Expect the (un)expected: a hazardous cause of tako-tsubo cardiomyopathy.

during percutaneous coronary intervention in patients with non-ST-segmentelevation acute coronary syndromes or stable ischemic heart disease: results from the evaluation of drug-eluting stents and ischemic events registry. Circ Cardiovasc Interv 2014 Apr 15.[Epub ahead of print].PMID: 24736878. 23. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55:2556–2566. 24. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797–804. 25. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601–1606. 26. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013;128: 1055–1065. 27. ClemmensenP, van’t HofA,Deliargyris EN,CosteP, ten Berg J,WibergS, CavalliniC, Hamon M, Dudek D, Zeymer U, Tabone X, Kristensen SD, Clayton T, Bernstein D, Prats J, Steg PG. Predictors associated with acute stent thrombosis after primary PCI: The EUROMAX Trial. J Am Coll Cardiol 2014;63(12S):A27.